Welcome to our dedicated page for Kneat Com news (Ticker: KSIOF), a resource for investors and traders seeking the latest updates and insights on Kneat Com stock.
KNEAT COM INC (OTCQX: KSIOF), also known as Kneat, regularly issues news updates that highlight its role in digitizing and automating validation and quality processes for highly regulated industries. Company announcements frequently cover new Master Services Agreements with global organizations in life sciences, healthcare technology, specialty chemicals, equipment manufacturing and related sectors, reflecting how its Kneat Gx platform is adopted across large, multi-site operations.
Investors and industry professionals following KSIOF news will see recurring themes around enterprise-scale deployments of Kneat Gx for computer systems validation, equipment validation, commissioning, qualification and validation (CQV), electronic logbooks, equipment testing workflows and drawing management processes. Many releases describe customers with operations in dozens of countries and thousands of employees, underscoring the platform’s use in complex, global environments.
Kneat’s news flow also includes financial results updates, where the company reports on total revenue, SaaS revenue, gross margin, and Annual Recurring Revenue (ARR), along with non‑IFRS metrics such as EBITDA and Adjusted EBITDA. These releases often discuss trends in new customer additions, expansions with existing customers and the company’s focus on scaling its SaaS business model.
Additional announcements highlight product evolution and AI capabilities, such as new versions of Kneat Gx that enhance data management, traceability, and support for risk-based validation approaches. Kneat also reports on external recognition, including leadership positions in G2 Pharma and Biotech software grids based on user satisfaction and market presence, and on events like its VALIDATE conference and investor presentations.
For readers interested in how digital validation and quality process automation are being adopted across life sciences and other regulated sectors, the KSIOF news page provides an ongoing view of Kneat’s customer wins, platform enhancements and financial performance.
Kneat (OTCQX: KSIOF, TSX: KSI) said it will release fourth-quarter and full-year 2025 financial results after TSX close on February 25, 2026. A webcasted conference call and Q&A with CEO Eddie Ryan and CFO Dave O’Reilly is scheduled for February 26, 2026 at 09:00 ET (14:00 GMT).
Financial results will be posted in the Financial Information section of Kneat’s investors page at https://kneat.com/investors/.
Kneat (OTCQX: KSIOF) on January 6, 2026 announced a Master Services Agreement with a Europe‑headquartered biopharma research and manufacturing technology provider that employs 13,000+ people and operates in more than 60 locations. The customer will begin deploying Kneat’s digital validation platform for equipment validation at several manufacturing sites worldwide.
Kneat said the vendor selection followed a comprehensive evaluation citing measurable ROI and prior life‑sciences deployments. Management expects the customer to expand use enterprise‑wide over time, and the agreement is presented as reinforcing Kneat’s market position and supporting continued revenue growth.
Kneat (OTCQX: KSIOF) signed a three-year Master Services Agreement with one of the world’s largest specialty chemicals makers on Dec 17, 2025, adding momentum to a record year for new customer additions.
The customer has a Europe HQ, a footprint in >100 countries, manufacturing in >24 countries, and >30,000 employees. Kneat will deploy Kneat Gx for Computer System Validation (CSV), Equipment Validation, and electronic logbooks. Kneat cites ease of use, no-code configurability, data integrity, and validation expertise as competitive strengths driving high win rates in 2025.
Kneat (OTCQX: KSIOF) reported Q3 2025 total revenue $16.1M, up 26% year over year, driven by SaaS revenue $15.2M (+33% YoY). Gross profit was $12.2M and gross margin held near prior levels at 76%. ARR reached $68.6M, up 37% YoY. Q3 EBITDA was $3.8M and Adjusted EBITDA was $2.5M; Q3 net loss was $0.5M. Year-to-date revenue rose 31% to $46.3M and YTD EBITDA improved to $13.5M. Management highlighted new three-year MSAs, G2 category rankings, and AI product advancements while hosting a webcast on Nov 13, 2025.
Kneat (OTCQC: KSIOF) has secured a significant Master Services Agreement with a major U.S.-based multinational manufacturer of advanced devices and components. The client company, which employs over 30,000 people across 30+ countries, will implement the Kneat Gx platform for two primary purposes:
The platform will be used for Computer Systems Validation across enterprise applications and for Commissioning, Qualification and Validation at 18 manufacturing sites within its medical and healthcare division. This strategic partnership demonstrates Kneat's expanding presence in the life sciences sector beyond pharmaceuticals.
Kneat (OTCQX: KSIOF), a leader in validation and quality process digitization, has achieved top rankings in G2's Fall 2025 Pharma and Biotech Software category reports. The company secured leadership positions in three categories with an impressive G2 Satisfaction Score of 98/100, surpassing the second-ranked company by 20 points.
The company earned leadership recognition in the Grid® Report, Relationship Index, and Mid-Market Grid® Report for Pharma and Biotech. Additionally, Kneat ranked second in the G2 Pharma and Biotech Usability Index, demonstrating strong performance in administration, ease of use, and requirements fulfillment.
Kneat (OTCQX:KSIOF), a leader in digitizing validation and quality processes for life sciences, will present at the Emerging Growth Conference on September 24, 2025, from 9:40 AM to 10:10 AM ET. CEO and co-founder Eddie Ryan will provide a company overview and discuss recent business progress.
The interactive online event will allow shareholders and investors to engage directly with management through a Q&A session. Kneat's flagship platform, Kneat Gx, enables life science companies to digitize validation processes, reduce risk, and accelerate product time-to-market. The company serves many leading global pharmaceutical companies.
Kneat (OTCQC: KSIOF) has secured a three-year Master Services Agreement with a major European equipment manufacturer that operates in multiple industries including healthcare. The unnamed company, which employs over 15,000 people and operates in 120+ countries, will implement Kneat's Gx platform to digitize equipment testing processes.
The deployment will initially begin at two strategic European sites. This marks Kneat's seventh strategic customer win in 2025, following a record-breaking quarter for new customer acquisitions. The partnership aims to enhance delivery quality and client handover processes through digital transformation.
Kneat (OTCQC: KSIOF) has secured a three-year Master Services Agreement with a global medical technology company, a division of a larger Asian manufacturer with over 30,000 employees operating in more than 160 countries. The client will implement the Kneat Gx platform for equipment validation processes.
CEO Eddie Ryan highlighted that this agreement reinforces the industry's confidence in Kneat's solutions within the life sciences sector. The company's growing platform functionality and adoption by major life sciences companies demonstrates Kneat's technical capabilities and strategic value in validation use cases.
Kneat (OTC: KSIOF) reported strong financial results for Q2 2025, with total revenue reaching $15.4 million, up 32% year-over-year. The company's SaaS revenue grew 31% to $14.1 million, while Annual Recurring Revenue (ARR) increased 43% to $64.8 million.
Q2 2025 highlights include improved gross margin of 75%, EBITDA of $3.8 million, and a reduced net loss of $0.4 million compared to a $3.1 million loss in Q2 2024. The company secured multiple significant client wins, including agreements with a multinational generic pharmaceuticals producer and a global healthcare technology company.
Kneat also announced key executive changes, including the appointment of Dave O'Reilly as CFO and the creation of a Chief Innovation Officer role. The company launched Kneat Gx 9.5, enhancing data management capabilities and validation processes.